Views & Analysis Dreaming big with small molecules Clovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved and on the market in less than a decade.
News Clovis hopes to get ahead of rivals in prostate cancer with ... Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca an
News Tesaro stock rockets as rumours of Roche takeover abound Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.
Oncology Clovis' Rubraca close to EU approval in ovarian cancer CHMP backs conditional approval for PARP drug
News 23andMe fined £2.31m over UK users' genetic data breach Genetic testing company 23andMe is facing a hefty fine from the UK's data protection watchdog for failing to protect its customers' data.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face